Cowen analyst Boris Peaker defended Mersana (NASDAQ: MRSN) after the company presented XMT-1536 ovarian data in 18 addt'l pts (n=47) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE